Sutro Biopharma’s CSO Trevor Hallam, Ph.D., wrote a guest blog in Scientific American, “Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter.” The article highlights the new efforts to improve antibody-drug conjugates (ADCs) from their first-generation counterparts.
With the recent FDA approval of Roche’s Kadcyla and Seattle Genetics’ Adcetris, the ADC space is heating up, and new technologies will further advance the next generation of ADCs. Sutro’s cell-free protein synthesis technology enables the incorporation of non-natural amino acids at any site in the antibody structure, resulting in single-species ADCs with site-specific conjugation of linker and drug. Because the ADCs can be synthesized rapidly and in parallel, hundreds of variants can be generated and screened quickly. This shortens development times to as little as weeks, as opposed to years. Sutro’s technology is currently used to create next-generation ADCs and bispecific antibodies.
Sutro is collaborating with Celgene Corporation, as well as some other biotech and pharmaceutical companies, on the design and development of next-generation ADCs and bispecific antibodies.